SCHEMBL4998779

SCHEMBL4998779

Cc1cccc2c1/C(=C\Nc1cccc(O)c1)C(=O)N2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
KDR P35968 2/20 0.47
PDPK1 O15530 1/20 0.47
RET P07949 4/20 0.46
ERBB2 P04626 2/20 0.43
MAPT P10636 2/20 0.43
GAA P10253 1/20 0.43
MAP3K7 O43318 1/20 0.43
TAB1 Q15750 1/20 0.43
PLK4 O00444 1/20 0.42
PLK1 P53350 1/20 0.42
FLT3 P36888 1/20 0.41
PDGFRB P09619 3/20 0.41
EGFR P00533 1/20 0.41
FGFR1 P11362 1/20 0.41
BRAF P15056 1/20 0.40
IGF1R P08069 1/20 0.39
MAOA P21397 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4998781 1.00 ALDH1A1 (0.55) ALDH1A1CYP1A2CYP3A4KDRPDPK1
SCHEMBL4996873 0.87 KDR (0.49) ALDH1A1CYP1A2CYP3A4KDRPDPK1
SCHEMBL4996878 0.87 KDR (0.49) ALDH1A1CYP1A2CYP3A4KDRPDPK1
SCHEMBL4999298 0.86 KDR (0.46) ALDH1A1CYP1A2CYP3A4KDRPDPK1
SCHEMBL4999295 0.86 KDR (0.46) ALDH1A1CYP1A2CYP3A4KDRPDPK1
SCHEMBL4995763 0.86 KDR (0.46) ALDH1A1CYP1A2CYP3A4KDRPDPK1
SCHEMBL4995765 0.86 KDR (0.46) ALDH1A1CYP1A2CYP3A4KDRPDPK1
SCHEMBL4994658 0.86 KDR (0.48) ALDH1A1CYP1A2CYP3A4KDRPDPK1
SCHEMBL4994655 0.86 KDR (0.48) ALDH1A1CYP1A2CYP3A4KDRPDPK1
SCHEMBL4992429 0.85 RET (0.58) ALDH1A1KDRPDPK1RETERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414054-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2008-08-19 US disclosed
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-08-31 US disclosed
US-7098236-B2 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-08-29 US disclosed
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-03-23 US disclosed
US-7015220-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-03-21 US disclosed
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-02-02 US disclosed
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2005-10-13 US disclosed
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ANDREWS STEVEN W (US) 2004-10-07 US disclosed
US-6765012-B2 FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION ALLERGAN, INC. 2004-07-20 US disclosed
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-12-04 US disclosed
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 ALDH1A1 1651/4885CYP1A2 3652/4885CYP3A4 4341/4885
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 ALDH1A1 1651/4885CYP1A2 3652/4885CYP3A4 4341/4885
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 ALDH1A1 1651/4885CYP1A2 3652/4885CYP3A4 4341/4885
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 ALDH1A1 1651/4885CYP1A2 3652/4885CYP3A4 4341/4885
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 ALDH1A1 1651/4885CYP1A2 3652/4885CYP3A4 4341/4885
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 ALDH1A1 1651/4885CYP1A2 3652/4885CYP3A4 4341/4885
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 ALDH1A1 1651/4885CYP1A2 3652/4885CYP3A4 4341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.